Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20(+) Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study

PURPOSE: Obinutuzumab (GA101), a novel glycoengineered type II anti-CD20 monoclonal antibody, demonstrated responses in single-arm studies of patients with relapsed/refractory non-Hodgkin lymphoma. This is the first prospective, randomized study comparing safety and efficacy of obinutuzumab with rit...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Sehn, Laurie H., Goy, Andre, Offner, Fritz C., Martinelli, Giovanni, Caballero, M. Dolores, Gadeberg, Ole, Baetz, Tara, Zelenetz, Andrew D., Gaidano, Gianluca, Fayad, Luis E., Buckstein, Rena, Friedberg, Jonathan W., Crump, Michael, Jaksic, Branimir, Zinzani, Pier Luigi, Padmanabhan Iyer, Swaminathan, Sahin, Deniz, Chai, Akiko, Fingerle-Rowson, Günter, Press, Oliver W.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2015
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5087315/
https://ncbi.nlm.nih.gov/pubmed/26282650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.59.2139
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires